Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers



Status:Terminated
Conditions:Gastrointestinal, Podiatry, Diabetes
Therapuetic Areas:Endocrinology, Gastroenterology, Orthopedics / Podiatry
Healthy:No
Age Range:18 - Any
Updated:12/14/2017
Start Date:February 2013
End Date:December 2015

Use our guide to learn which trials are right for you!

A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus

The purpose of the study is to determine if DSC127 is effective in increasing incidence of
complete wound closure at 10 weeks confirmed at a visit 2 weeks later when compared to the
vehicle (gel without active ingredient) in subjects with diabetes mellitus (DM) who have
chronic Wagner Grade 1 or 2 plantar neuropathic foot ulcers, 0.75 - 6 cm2 in size.

Subjects will undergo a two week screening period to assess plantar ulcer healing, and those
healing less than 30% will be eligible for randomization, providing they meet all other
inclusion criteria. Four weeks of blinded "treatment" follows the screening period, and an
observation period of six weeks (to 10 weeks post first treatment) follows the 4-week
treatment period. If the ulcer closes during the treatment or observation period, the closure
will be confirmed two weeks later, and at this time the subject enters a durability
assessment period of up to 12 weeks.

All aspects of Standard of Care are followed throughout the study period.

Inclusion Criteria:

1. Male or female ambulatory subject age ≥18 years at the time of informed consent

2. Has type 1 or type 2 DM under metabolic control as confirmed by a glycosylated
hemoglobin (HbA1c) of ≤12% and a serum creatinine level of ≤3mg/dL

3. At Screening and at Baseline (prior to randomization), subject has at least one ulcer
that fulfills all of the following criteria:

- Present for ≥1 month and ≤1 year

- Partial- or full- thickness and not involving bone, tendon, or capsule (probing
to tendon or capsule), i.e. Wagner Grade 1 or 2

- Has no sign of infection or osteomyelitis

- Plantar neuropathic ulcer; ulcer must be predominantly on the plantar surface of
the foot to ensure adequate off-loading and may include the toes

- Size of the target ulcer must be 0.75 - 6 cm2

- Target ulcer must be non-healing as defined as <30% reduction in size in response
to standard of care during the two week Screening Period

- If more than one ulcer is present that meets the inclusion criteria, the
largest one will be considered the Target ulcer.

- If there are two ulcers of the same size that meet all criteria, the one
with the higher Wagner Grade will be considered the Target ulcer.

- If there are two ulcers of the same size and the same Wagner Grade, the one
present for the longest qualifying time will be the Target ulcer.

4. Has an ankle brachial index (ABI) ≥ 0.7 on the foot with the target ulcer

5. Has an assessment of the baseline level of neuropathy of the foot using
Semmes-Weinstein filaments.

6. A female subject of childbearing potential must have a negative serum pregnancy test
at the time of Screening, and must be willing to use a medically acceptable method of
birth control, such as Essure®, hormonal contraception (oral pills, implantable
device, or skin patch), intrauterine device, tubal ligation, or double barrier
throughout the study. A female subject of childbearing potential who practices
abstinence is not required to employ birth control.

7. Has the ability and willingness to understand and comply with study procedures and to
give written informed consent prior to enrollment in the study or initiation of study
procedures

Exclusion Criteria:

1. Has a known hypersensitivity to any of the investigational drug or vehicle components

2. Has been exposed to any investigational agent within 30 days of entry into the study

3. A female who is pregnant or nursing

4. Has active malignant disease of any kind except for basal cell carcinoma (of the
skin). A subject, who has had a malignant disease in the past, was treated and is
currently disease-free, may be considered for study entry.

5. Has a hemoglobin of less than 8.5 gm/dL.

6. Transaminase levels greater than 3 × normal

7. Is receiving hemodialysis or chronic ambulatory peritoneal dialysis (CAPD) therapy

8. Has had prior radiation therapy of any part of the foot with the target ulcer under
study

9. Use of systemic corticosteroids and immunosuppressants (within the 8 weeks prior to
screening)

10. Has an ulcer primarily ischemic in etiology

11. Has sickle-cell anemia, Reynaud's, or other peripheral vascular disease

12. Has received a biologic agent, growth factors or skin equivalents (Regranex®,
Apligraft, or Dermagraft), in the past 30 days

13. Has a target ulcer which is determined to be clinically infected and requires
antimicrobials. Any antibiotic therapy must be completed or discontinued at screening.

14. Has a Wagner Grade 3 or greater DFU, deep abscess, or gangrene

15. Has uncontrolled hypertension, in the opinion of the Investigator.

16. Any other finding, which in the opinion of the Investigator, may interfere with the
assessment of the product or participation of the subject in the study.
We found this trial at
25
sites
Greenville, North Carolina 27834
?
mi
from
Greenville, NC
Click here to add this to my saved trials
8042 Wurzbach Road
San Antonio, Texas 78229
210-949-0807
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Aiken, South Carolina 29801
?
mi
from
Aiken, SC
Click here to add this to my saved trials
1 Boston Medical Center Place
Boston, Massachusetts 02118
617.638.8000
Boston University Medical Center Boston Medical Center is an extraordinary community of health care providers...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chattanooga, Tennessee 37421
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
4500 S. Lancaster Rd.
Dallas, Texas 75216
800-849-3597
Dallas VA Medical Center VA North Texas Health Care System (VANTHCS) is a progressive health...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Eugene, Oregon 97401
?
mi
from
Eugene, OR
Click here to add this to my saved trials
Fair Oaks, California 95628
?
mi
from
Fair Oaks, CA
Click here to add this to my saved trials
Fort Worth, Texas 76104
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Fresno, California 93710
?
mi
from
Fresno, CA
Click here to add this to my saved trials
Granger, Indiana 46530
?
mi
from
Granger, IN
Click here to add this to my saved trials
Homestead, Florida 33035
?
mi
from
Homestead, FL
Click here to add this to my saved trials
Jacksonville, Florida 32209
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
LaPorte, Indiana 46350
?
mi
from
LaPorte, IN
Click here to add this to my saved trials
Los Angeles, California 90010
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
286 Westward Drive
Miami, Florida 33176
?
mi
from
Miami, FL
Click here to add this to my saved trials
Miami Lakes, Florida 33016
?
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
Mobile, Alabama 36608
?
mi
from
Mobile, AL
Click here to add this to my saved trials
North Miami Beach, Florida 33013
?
mi
from
North Miami Beach, FL
Click here to add this to my saved trials
Pismo Beach, California 93449
?
mi
from
Pismo Beach, CA
Click here to add this to my saved trials
Portland, Oregon 97232
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
Roanoke, VA
Click here to add this to my saved trials
1839 Central Avenue
Saint Petersburg, Florida 33713
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Sylmar, California 91342
?
mi
from
Sylmar, CA
Click here to add this to my saved trials
Tustin, California
?
mi
from
Tustin, CA
Click here to add this to my saved trials